MS Speaks
Multiple Sclerosis => TREATMENTS => Topic started by: agate on May 11, 2019, 02:32:11 pm
-
Abstract of a paper presented at the annual AAN conference (Philadelphia, May 4-10, 2019) by researchers at the Cleveland Clinic entitled "Early Impact of Natalizumab Switch to Moderate Versus High Efficacy Disease Modifying Therapy in Clinical Practice":
http://indexsmart.mirasmart.com/AAN2019/PDFfiles/AAN2019-000892.pdf